Sartorius Stedim Biotech (DIM) Q3 2024 earnings summary

Executive summary

• Nine-month 2024 results are in line with expectations, with guidance for the full year confirmed across all metrics.

• Sales revenue nearly matched prior-year levels, with significant order intake growth and robust profitability; recurring business and consumables showed positive momentum.

• Profitability remains robust, supported by an ongoing efficiency program and strong cash flow from reduced working capital and CapEx management.

• The business environment is stabilizing, with normalization trends in order patterns and customer destocking nearing completion.

• Efficiency program delivered increasing positive effects, with the largest contribution expected in Q4.

Financial highlights

• Group sales revenue: €2,474m (-2.8% year-over-year); order intake: €2,326m (+5.7% year-over-year); underlying EBITDA margin for nine months is 27.7%.

• Free cash flow increased to €280 million for nine months, with Q3 contributing €180 million; operating cash flow: €613m (+13.0% year-over-year).

• CapEx as a percentage of sales is down to 12.9% after three quarters.

• Underlying EPS (ord.): €3.01 (-24.6% year-over-year); underlying EPS (pref.): €3.02 (-24.6% year-over-year).

• Net debt reduced to €3,946m; net debt to underlying EBITDA at 4.3–4.4x.

Outlook and guidance

• Full-year 2024 guidance confirmed: sales revenue expected at prior-year level, EBITDA margin 27–29%, capex ratio around 12%.

• Efficiency program expected to deliver over €100 million in 2024, with the largest impact in Q4.

• Acquisitions projected to contribute around 2% to sales revenue.

• Net debt to EBITDA ratio targeted between 2.5 and 4 at year-end.